Ricevi le ultime notizie sulle azioni Arvinas con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ARVN

Ultime notizie per

ARVINAS INC

Arvinas

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Pfizer logo on building

Long Ideas

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ARVN

XRAY

Cerchi rendimenti stabili? Tre titoli nel settore sanitario mostrano un potenziale interessante. Un&#39;analisi approfondita per investitori.

Titoli a dividendo: 3 occasioni nel settore sanitario per il tuo portafoglio

Dividend,Growth,And,Profits,With,Finger,Pointing,On,The,Graph.

SPRO

Questi colossi del settore della salute offrono rendimenti solidi e hanno il sostegno di alcuni dei nomi più affidabili del settore.

3 titoli a dividendo scelti dagli analisti più &#34;precisi&#34; di Wall Street

Northeastern States Rank High

IOVA

Analizziamo le aziende con RSI basso, che potrebbero offrire interessanti opportunità di profitto nel mercato finanziario. Ecco i nomi.

3 titoli del settore sanitario destinati a decollare nel prossimo trimestre

Arvinas Inc

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

Biotech

General

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Legal

Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm

Management

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Earnings

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Biotech's Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM,  ENTA)

BNTX

ENTA

MDCX

ONCY

RYTM

SMLR

TSX:ONC

Alumis

ALT5 Sigma

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Canopy Growth Corporation - Common Shares

Canopy Growth

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

Maze Therapeutics

MBX Biosciences

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine

Nektar Therapeutics

Omeros

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

HC Wainwright & Co.

Wells Fargo

Guggenheim

Leerink Partners

Comments

Arvinas Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO